Clinical Trials · NCT00831233

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

TerminatedPhase 3Gonadorelin (Prohibited)
Phase
Phase 3
Recruitment status
Terminated
Sponsor
Ferring Pharmaceuticals
Enrollment
42
Start date
Apr 2009
Locations
33 sites, 3 countries
Primary endpoint
Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12
View Gonadorelin compound reference